The significant inter- and intra-tumor heterogeneity observed in breast cancer patients presents an ongoing challenge that impedes accurate disease characterization and classification, thereby affecting precise patient stratification. Breast cancer subtyping methods, including immunohistochemistry (IHC) and PAM50 gene expression profiling, play a significant role in addressing this challenge. Our primary objective is to measure the predictive accuracy of intermediate fusion techniques utilizing SNF or RWR, while refining and characterizing existing breast cancer subtypes.